Impower110: Interim OS Analysis of a Phase III Study Of Atezolizumab (ATEZO) vs Platinum-Based Chemotherapy (Chemo) as 1L Treatment (TX) in PD-L1-Selected NSCLC
dc.contributor.author | Enquist, Ida | |
dc.contributor.author | Kotnatsubara, Kim | |
dc.contributor.author | Deng, Yu | |
dc.contributor.author | Kuriki, Hiroshi | |
dc.contributor.author | Wen, Xiaohui | |
dc.contributor.author | Jassem, Jacek | |
dc.contributor.author | Reinmuth, Niels | |
dc.contributor.author | Spigel, David | |
dc.contributor.author | De Marinis, Filippo | |
dc.contributor.author | Giaccone, Giuseppe | |
dc.contributor.author | Verynenegre, Alain | |
dc.contributor.author | Barrios, Carlos Henrique | |
dc.contributor.author | Morise, Masahiro | |
dc.contributor.author | Felip, Enriqueta | |
dc.contributor.author | Andric, Zoran | |
dc.contributor.author | Geater, Sarayut | |
dc.contributor.author | Ozgueroglur, Mustafa | |
dc.contributor.author | Mocci, Simonetta | |
dc.contributor.author | Mccleland, Mark | |
dc.contributor.author | Herbst, Roy S. | |
dc.date.accessioned | 2021-03-05T18:32:12Z | |
dc.date.available | 2021-03-05T18:32:12Z | |
dc.identifier.citation | Reinmuth N., Spigel D., De Marinis F., Giaccone G., Verynenegre A., Barrios C. H. , Morise M., Felip E., Andric Z., Geater S., et al., "Impower110: Interim OS Analysis of a Phase III Study Of Atezolizumab (ATEZO) vs Platinum-Based Chemotherapy (Chemo) as 1L Treatment (TX) in PD-L1-Selected NSCLC", ONCOLOGY RESEARCH AND TREATMENT, cilt.43, ss.232-233, 2020 | |
dc.identifier.issn | 2296-5270 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_cacec438-672a-4d4b-ba1a-9da01b4e77a6 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/134353 | |
dc.language.iso | eng | |
dc.subject | Onkoloji | |
dc.subject | ONKOLOJİ | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.title | Impower110: Interim OS Analysis of a Phase III Study Of Atezolizumab (ATEZO) vs Platinum-Based Chemotherapy (Chemo) as 1L Treatment (TX) in PD-L1-Selected NSCLC | |
dc.type | Makale | |
dc.relation.journal | ONCOLOGY RESEARCH AND TREATMENT | |
dc.contributor.department | Roche Holding , , | |
dc.identifier.volume | 43 | |
dc.identifier.startpage | 232 | |
dc.identifier.endpage | 233 | |
dc.contributor.firstauthorID | 2277643 |
Bu öğenin dosyaları:
Dosyalar | Boyut | Biçim | Göster |
---|---|---|---|
Bu öğe ile ilişkili dosya yok. |
Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.
-
Makale [92796]